Eggersdorfer, M., & Wyss, A
Novel agents Looking to the next generation of obesity treatments, oral GLP-1 receptor agonists and combinations of GLP-1 receptor agonists with other enteropancreatic hormones (such as GIP agonists, glucagon receptor agonists and amylin analogues) are under investigation to enhance the weight loss and cardiovascular benefits of GLP-1 agonists
Nonetheless, its recommended that you speak with your doctor before taking urolithin A even if youre perfectly healthy and not on any prescription medication
Some people might drop a couple of pounds, while others could lose 10 pounds or much more than that
1.1 Expanded indications and increasing disease prevalence In addition to type 2 diabetes and weight management as key battlegrounds today, GLP-1 therapies have shown clinical promise in treating a wider array of conditions, including Alzheimers disease, cardiovascular risk reduction , MASH (metabolic dysfunction-associated steatohepatitis) and chronic kidney disease (CKD)
